Clinical efficacy and safety of fucoidan for biochemical recurrence after radical prostatectomy

Clinical efficacy and safety of fucoidan for biochemical recurrence after radical prostatectomy - Fucoidan for prostate cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005432

Enrollment

Registered

2012-12-01

Start date

2012-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Fucoidan (Marine Products Kimuraya Co.Ltd., Japan)

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) sequential 2 points of 0.2ng/ml or more of serume PSA level, after radical prostatectomy for organ-confined prostate cancer 2) obtaining of informed consent in writing

Exclusion criteria

Exclusion criteria: 1) undergoing hormonal therapy 2) suspecting of distant metastasis 3) severe comorbidities 4) during 3 mo. before attempt of fucoidan intervention, receiving any types of complementary/alternative medicine 5) inappropriate, judged by doctor

Design outcomes

Primary

Measure	Time frame
Partial regression rate accoriding to PSA level, at 6mo. after intervention	—

Secondary

Measure	Time frame
1) rate of improvement of PSA slope,, at 6mo. after intervention 2) alteration of testosterone level 3) safety	—

Countries

Japan

Contacts

Public ContactKoji Yoshimura

Kyoto University Graduate School of Medicine Urology

ky7527@kuhp.kyoto-u.ac.jp075-751-3337

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026